Keun-Wook Lee1, Ju Hyun Lee1, Jin Won Kim1, Ji-Won Kim1, Soyeon Ahn2, Jee Hyun Kim3. 1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea. 2. Division of Statistics, Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea. 3. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea. jhkimmd@snu.ac.kr.
Abstract
PURPOSE: Older patients with cancer are underrepresented in clinical trials, and thus, limited data are available on older patients with metastatic gastric cancer (MGC). This study was conducted to assess patterns of care, and outcomes of chemotherapy and its predictors, in older patients with MGC. METHODS: Using the Korean Health Insurance Review and Assessment Service (HIRA) database, a nationwide population-based outcomes study was conducted. From the HIRA database, patients newly diagnosed with MGC in 2010 were identified (N = 1871). RESULTS: Patients aged ≥70 years were defined as older patients (N = 792) and those aged <70 years as younger patients (N = 1079). Compared with younger patients, fewer older patients were diagnosed with MGC and received cancer treatment at high-volume medical institutions. Palliative chemotherapy was less frequently administered in older patients than in younger patients. In multivariate analyses, although combination chemotherapy as the first-line treatment (vs. monotherapy) and salvage chemotherapy after first-line chemotherapy (vs. no salvage chemotherapy) conferred more prolonged survival in the entire patient population, first-line combination chemotherapy did not provide an additional survival benefit in older patients compared to monotherapy. CONCLUSIONS: We found several barriers for older patients in approaching high-quality medical resources or receiving appropriate treatments. Although age was not an independent prognostic factor for survival in MGC, palliative chemotherapy was less frequently used in older patients. In our analysis, combination chemotherapy as the first-line treatment did not provide an additional benefit to older patients compared to monotherapy.
PURPOSE: Older patients with cancer are underrepresented in clinical trials, and thus, limited data are available on older patients with metastatic gastric cancer (MGC). This study was conducted to assess patterns of care, and outcomes of chemotherapy and its predictors, in older patients with MGC. METHODS: Using the Korean Health Insurance Review and Assessment Service (HIRA) database, a nationwide population-based outcomes study was conducted. From the HIRA database, patients newly diagnosed with MGC in 2010 were identified (N = 1871). RESULTS:Patients aged ≥70 years were defined as older patients (N = 792) and those aged <70 years as younger patients (N = 1079). Compared with younger patients, fewer older patients were diagnosed with MGC and received cancer treatment at high-volume medical institutions. Palliative chemotherapy was less frequently administered in older patients than in younger patients. In multivariate analyses, although combination chemotherapy as the first-line treatment (vs. monotherapy) and salvage chemotherapy after first-line chemotherapy (vs. no salvage chemotherapy) conferred more prolonged survival in the entire patient population, first-line combination chemotherapy did not provide an additional survival benefit in older patients compared to monotherapy. CONCLUSIONS: We found several barriers for older patients in approaching high-quality medical resources or receiving appropriate treatments. Although age was not an independent prognostic factor for survival in MGC, palliative chemotherapy was less frequently used in older patients. In our analysis, combination chemotherapy as the first-line treatment did not provide an additional benefit to older patients compared to monotherapy.
Entities:
Keywords:
Chemotherapy; Gastric cancer; Older patients; Outcomes research
Authors: Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Der Sheng Sun; Eun Kyoung Jeon; Hye Sung Won; Ji Chan Park; Byoung Young Shim; Suk Young Park; Young Seon Hong; Hoon Kyo Kim; Yoon Ho Ko Journal: Gastric Cancer Date: 2014-08-07 Impact factor: 7.370
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: H S Kim; H J Kim; S Y Kim; T Y Kim; K W Lee; S K Baek; T Y Kim; M H Ryu; B H Nam; D Y Zang Journal: Ann Oncol Date: 2013-08-13 Impact factor: 32.976
Authors: In Sil Choi; Mihong Choi; Ju Hyun Lee; Jee Hyun Kim; Koung Jin Suh; Ji Yun Lee; Beodeul Kang; Ji-Won Kim; Se-Hyun Kim; Jin Won Kim; Jeong-Ok Lee; Yu Jung Kim; Soo-Mee Bang; Jong Seok Lee; Keun-Wook Lee Journal: PLoS One Date: 2018-06-07 Impact factor: 3.240
Authors: Jin Won Kim; Jong Gwang Kim; Byung Woog Kang; Ik-Joo Chung; Young Seon Hong; Tae-You Kim; Hong Suk Song; Kyung Hee Lee; Dae Young Zang; Yoon Ho Ko; Eun-Kee Song; Jin Ho Baek; Dong-Hoe Koo; So Yeon Oh; Hana Cho; Keun-Wook Lee Journal: Cancer Res Treat Date: 2018-10-19 Impact factor: 4.679
Authors: In Sil Choi; Jee Hyun Kim; Ju Hyun Lee; Koung Jin Suh; Ji Yun Lee; Ji-Won Kim; Se-Hyun Kim; Jin Won Kim; Jeong-Ok Lee; Yu Jung Kim; Soo-Mee Bang; Jong Seok Lee; Keun-Wook Lee Journal: PLoS One Date: 2018-10-22 Impact factor: 3.240